MétaCan
Menu
Back to cohort
Record W4388343130 · doi:10.1016/j.ctarc.2023.100774

Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence

2023· article· en· W4388343130 on OpenAlexafffund
Niki Esfahanian, Sze Wah Samuel Chan, Luna Jia Zhan, M. Catherine Brown, Khaleeq Khan, Jae Lee, Karmugi Balaratnam, Elizabeth Yan, Jennifer J. Parker, Miguel García-Pardo, Samir H. Barghout, Lawson Eng, Penelope A. Bradbury, Frances A. Shepherd, Natasha B. Leighl, Adrian G. Sacher, Stephanie Snow, Rosalyn A. Juergens, Geoffrey Liu

Bibliographic record

VenueCancer Treatment and Research Communications · 2023
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsJuravinski Cancer CentrePrincess Margaret Cancer CentreMcMaster UniversityDalhousie UniversityUniversity of TorontoUniversity Health Network
FundersAmgen Canada
KeywordsMedicineHazard ratioInternal medicineStage (stratigraphy)OncologyTargeted therapyProgressive diseaseLung cancerCancerDiseaseGastroenterologyConfidence interval

Abstract

fetched live from OpenAlex

Close monitoring after diagnosis of patients with stage I-III non-small cell lung cancer (NSCLC) may result in fitter patients with lower disease burden at the time of metastatic recurrence or progression compared to patients diagnosed initially as stage IV (de novo). We compared the presentation, treatments, and outcomes of patients with KRASG12C-mutated NSCLC with de novo versus recurrent stage IV disease. Of 109 patients, 94% had a smoking history. When compared to patients with KRASG12C-mutated NSCLC who developed stage IV disease at recurrence (n=38), de novo stage IV patients (n=71) had worse ECOG performance status (p=0.007), greater numbers of extra-thoracic metastatic sites (p=0.001), and were less likely to receive 2nd/3rd line systemic therapy (p=0.05, p=0.002) or targeted therapy (p=0.001). De novo metastatic patients had shorter overall survival than metastatic patients at recurrence (9.1 versus 24.2 months; adjusted-hazard-ratio=1.94 (95%CI:1.14-3.28; p=0.01)). There is a critical need for well-tolerated targeted therapies in the first-line setting for metastatic patients with de novo, high-burden, stage IV KRASG12C-mutated NSCLCs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.078
GPT teacher head0.443
Teacher spread0.365 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueCancer Treatment and Research CommunicationsSame topicLung Cancer Treatments and MutationsFrench-language works237,207